Type 1 Diabetes Extension Study

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Apr 6, 2016

Keywords

ClinConnect Summary

The Type 1 Diabetes Extension Study is a research project looking at the long-term effects of certain treatments for Type 1 Diabetes (T1D). This study is designed for people who have previously participated in selected studies involving new treatments aimed at modifying the immune system. The main goals are to see how long participants can continue to produce insulin, which is the hormone that helps control blood sugar levels, and to understand how changes in the immune system over time affect this insulin production. This information could help researchers develop better treatments for Type 1 Diabetes in the future.

To be eligible for this study, participants must have previously taken part in an approved Type 1 Diabetes study by the Immune Tolerance Network (ITN) and be able to give their consent to join the study. There are a few health conditions that might prevent someone from safely participating, so the study team will review each person's medical history. If someone joins, they can expect regular check-ins to monitor their health and insulin production over time. Overall, the study aims to gather important information that could improve diabetes care for everyone affected by this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
• • Ability to sign informed consent/assent (as applicable for children).
• Exclusion Criteria:
• • Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
• • Inability to comply with the study visit schedule and required assessments.